{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 37,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-based visual to show disease progression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/15",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.4,
        "x": 0.55,
        "y": 0.17
      },
      "kind": "framework",
      "text": "The Progressive Impact of Persistently High Plasma Arginine",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2348f44f-b34a-4b22-bc06-2f2ca3b3323c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "list",
      "text": "Current Standard of Care: Focused on lowering plasma arginine levels and controlling hyperammonemia with: Severe dietary protein restriction, Amino acid supplementation, Ammonia scavengers. Ineffective at controlling plasma arginine levels.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d287fb6-7638-400a-8058-60cbcb1268ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.07,
        "y": 0.66
      },
      "kind": "list",
      "text": "Significant Unmet Need: High arginine levels, Severe and progressive disease with early mortality, Easily diagnosed but often missed due to lack of awareness, No approved therapies to address high arginine levels.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61ddac90-c7f9-41a7-8e87-3ee13ed7184a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.43,
        "x": 0.07,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "ARG1-D is a serious, progressive disease with early mortality and high unmet medical need. It is caused by a mutation in the arginase 1 enzyme, resulting in persistently high levels of arginine.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9788e7eb-0f1c-4fe8-9575-9d7dfff6939d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "1 Diez-Fernandez C, et al. Hum Mutat. 2018;39:1029-1050. 2 Carvalho DR, et al. Pediatr Neurol. 2012;46:369-374. 3 Crombez EA, Cederbaum SD. Mol Genet Metab. 2005;84:243-251. 4 De Deyn PP, et al. Hyperargininemia: a treatable inborn error of metabolism.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76a7b5c0-4fa4-473f-9155-4faa4fa2c1c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Arginase 1 Deficiency (ARG1-D) Disease Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50924bde-a3f2-4772-9b42-7e0823e6d7ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "customer-journey",
      "slug": null,
      "matchId": "64338a7b-dcb7-448b-9244-074ab1bf7f5c",
      "evidence": "Visual timeline showing disease progression from infancy to adulthood.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "4114b6df-d0d5-47ec-bd8a-a18d8b41ce51",
      "evidence": "The document presents positive results from the Phase 3 clinical trial",
      "position": 1,
      "objective": "Show the potential of Pegzilarginase to improve patient outcomes",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}